ClinicalTrials.gg

Malaria clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,185 studies for Malaria across more than 10 countries. 80 are recruiting or about to start. 884 of them are mainly about Malaria (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 2 narrower conditions too, such as Malaria, Falciparum: 1,428 studies, 110 open.

ClinicalTrials.gov finds 1,490 studies for Malaria. How that becomes 1,184 here

This page counts the studies the registry files under Malaria, and those it files under no condition that list Malariathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,490Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −242Filed under a narrower condition, counted on its own pageMalaria, Falciparum 182 · Malaria, Vivax 56
  3. −17List Malaria as a condition, but the registry did not file them under itMost often written as “Cerebral Malaria” (4), “Malaria in Pregnancy” (3), and “Malaria Parasitaemia” (2). The registry filed them under other conditions only, most often Malaria, Cerebral (6) and Anemia (5).
  4. −47Match it another way38 name it in the title, 3 in a keyword, and 6 by a synonym or other text the search reads.
  5. 1,184The count on this page47 of them list Malaria in their own words; the registry filed them under no condition.

Status

Completed
900
Status unknown
95
Recruiting
52
Terminated
40
Withdrawn
33
Active, not recruiting
32

Phase

Phase 1
268
Phase 2
184
Phase 3
174
Phase 4
172
Early Phase 1
6

Where

United States
105
Burkina Faso
100
Uganda
98
Kenya
94
Mali
90
Tanzania
78

Who develops what

Add Malaria to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 16 programs from 6 companies, 12 with this as their studies’ main aim; 0 with a live phase 3 study; 4 primary completions in the next 12 months. Compare Serum Institute of India Pvt., GlaxoSmithKline and Sanaria here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
R21Recent, limited
Evidence
  • NCT07147400 · Serum Institute of India Pvt. Ltd. · Phase 2 · live · background · “R21 Malaria Vaccine (Recombinant) For Bedside Mixing” · registered Aug 2025
—11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 16 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Feb 2027 est.Genetically attenuated PfSPZ Vaccine · Sanaria Inc. · Phase 2 named, not the main aimNCT07385287 Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults — primary endpoint: Vaccine efficacy of PfSPZ-LARC2 Vaccine as compared to normal saline, placebo against first Pf infection as detected by thick blood smear (TBS). · 180 enrolled
  • 23 Apr 2027 est.as01e · GlaxoSmithKline · Phase 2 main aimNCT07036159 A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months — primary endpoint: Geometric Mean Concentrations (GMCs) of anti-NANP immunoglobulin G (IgG) antibodies · 238 enrolled
  • 8 Oct 2027 est.GSK3772701 · GlaxoSmithKline · Phase 2 named, not the main aimNCT07545681 A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria — primary endpoint: Number of participants with serious adverse events (SAEs) overall, treatment related, and by severity · 70 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Malaria studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antimetabolites 2 open

Coming up

28studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 52 Malaria studies recruiting now, 15 (29%) set no upper age limit and 34 (65%) stop at 75 or younger. 38 (73%) take children under 18. 9 (17%) are for women only and 0 (0%) for men only; 32 (62%) take healthy volunteers.

Recruiting studies that take each age, of 52
AgeWomenMen
1019 (37%)19 (37%)
1835 (67%)26 (50%)
3035 (67%)27 (52%)
4034 (65%)27 (52%)
5029 (56%)25 (48%)
6523 (44%)19 (37%)
7519 (37%)15 (29%)
8518 (35%)14 (27%)

Across all 1,185 studies, recruiting or not: 68% stop at 75 or younger and 67% at 65; 65% take children; 9% are for women only and 3% for men only; 57% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Malaria studies take

Of 93 phase 1 interventional studies under Malaria, half reached primary completion within 13 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 113 mo7–20 · 93 studies11 mo6–18 · 29 studies13 mo7–24 · 64 studies
Phase 1/218 mo8–32 · 16 studies——
Phase 216 mo10–27 · 39 studies——
Phase 323 mo17–31 · 50 studies—23 mo20–34 · 44 studies
Phase 419 mo7–32 · 50 studies—18 mo7–29 · 49 studies
Interventional, no phase23 mo8–33 · 101 studies—23 mo11–35 · 95 studies
Observational24 mo16–44 · 93 studies—23 mo13–36 · 85 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,185. Browse all 1,185 → or search them.